CCR10 (C-C Chemokine Receptor 10) is a G protein-coupled receptor (GPCR) within the chemokine receptor family. It binds with high affinity to its primary ligand CCL27 (also known as CTACK), and to a lesser extent CCL28, orchestrating the targeted migration of immune cells—particularly T lymphocytes and plasma cells—to epithelial tissues like the skin, salivary glands, colon, and respiratory mucosa.

Because of its tissue-specific homing function, CCR10 has emerged as a valuable target for monoclonal antibody development for applications in cancer immunotherapy, autoimmune disorders, mucosal immunity, and inflammatory diseases.

CCR10 is highly expressed on skin-homing T cells and IgA-secreting plasma cells in mucosal tissues.

• In the skin, the CCL27–CCR10 axis recruits effector memory T cells (Tem) during inflammation and cutaneous immune surveillance.

• In mucosal tissues, especially the gut and lungs, CCL28–CCR10 signaling supports the migration of IgA+ plasma cells, which are critical for mucosal barrier defense.

Disruption of CCR10 signaling is associated with chronic inflammation, autoimmune disease, and epithelial cancers—making it a prime focus for monoclonal antibody R&D and therapeutic targeting.

CCR10 is not only a migration receptor—it’s also a regulatory checkpoint in immune responses.

• In conditions like atopic dermatitis and psoriasis, overexpression of CCL27 and upregulation of CCR10 on T cells perpetuate skin inflammation.

• In inflammatory bowel disease (IBD), CCR10-expressing IgA+ plasma cells and mucosal T cells contribute to persistent intestinal inflammation.

• Blocking the CCR10–CCL27/CCL28 axis using monoclonal antibodies to CCR10 could provide a novel therapeutic avenue to resolve tissue-specific chronic inflammation.

CCR10 is increasingly recognized as a contributor to tumor immune evasion.

• Melanoma, breast cancer, cervical cancer, and colorectal cancer show aberrant expression of CCL27 or CCL28, which attracts CCR10+ regulatory T cells (Tregs) and immunosuppressive plasma cells into the tumor microenvironment.

• This recruitment facilitates immune escape and tumor progression.

• Anti-CCR10 monoclonal antibodies can block the homing of suppressive immune cells to tumors.

• Preclinical studies suggest that CCR10-targeting antibodies enhance antitumor immunity, particularly in combination with checkpoint inhibitors like anti-PD-1 or anti-CTLA-4.

CCR10 monoclonal antibodies are critical for:

• Flow cytometric analysis of CCR10 expression on tissue-specific T cells and plasma cells

• Immunohistochemistry (IHC) of CCR10 expression in healthy and diseased tissues

• In vivo functional studies targeting CCR10 in mouse models of cancer, skin inflammation, and mucosal immunity

High-affinity monoclonal antibodies against CCR10 are essential tools in immunology, oncology, and mucosal research.

CCR10 is a biomarker for:

• Tissue-specific inflammation (e.g., dermatitis, IBD)

• T cell subtypes in skin, salivary gland, and mucosal immunity

• Tumor-infiltrating immune cells with immunosuppressive properties

Diagnostic-grade anti-CCR10 monoclonal antibodies enable immune profiling and biopsy evaluation, particularly in personalized medicine.

CCR10 monoclonal antibodies are being investigated in therapeutic pipelines targeting:

• Skin disorders (e.g., psoriasis, atopic dermatitis)

• Inflammatory bowel diseases (e.g., Crohn’s, ulcerative colitis)

• Mucosal cancers and metastatic melanoma

• Chronic viral infections in mucosal tissues

By blocking CCR10, these antibodies can reduce inappropriate immune cell infiltration, resolve chronic inflammation, and restore mucosal immunity.

Monoclonal antibodies to CCR10 are powerful tools in both research and clinical development, enabling precision-targeted studies and interventions in cancer, chronic inflammation, and autoimmune disease.

Whether you're investigating mucosal immunity, tumor immunosuppression, or cutaneous inflammation, CCR10-targeted antibodies offer a high-value platform for discovery and therapeutic advancement.

SYnAbs provides a full range of monoclonal antibodies against CCR10 for:

• Research use only (RUO)

• Diagnostic assay development

• Preclinical and therapeutic evaluation

Backed by validated specificity, high affinity, and cross-species reactivity for human and mouse targets.